PL EN


Preferences help
enabled [disable] Abstract
Number of results
Journal
2017 | 4 | 1 | 15-23
Article title

Diagnostyka i leczenie centralnej surowiczej chorioretinopatii

Authors
Content
Title variants
EN
Diagnosis and treatment of central serous chorioretinopathy
Languages of publication
PL
Abstracts
EN
Central serous chorioretinopathy (CSC, CSCR) may lead to visual impairment, mostly in men between 20–55 years of age. It presents as a typical serous neurosensory retinal detachment and accumulation of subretinal fluid in the centre of the macula. Type A personality, high-stress occupations and corticosteroid therapy have been associated with CSC prevalence. Fluorescein angiography, optical coherence tomography or indocyanine green angiography have been used for diagnosis. Central serous chorioretinopathy is typically a self-limited disease, but about 20% of the cases may be affected by the persistent form of CSC. Central serous chorioretinopathy is successfully treated with laser therapy or anti-VEGF inhibitors. Oral therapies offer a very promising approach, but further prospective randomized trials are required to provide more data.
PL
Centralna surowicza chorioretinopatia (CSR, CSCR) bywa przyczyną pogorszenia widzenia, w większości u mężczyzn między 20. a 55. r.ż. Charakteryzuje się odwarstwieniem neurosensorycznej siatkówki i gromadzeniem się płynu podsiatkówkowego w centrum plamki. Z występowaniem CSR mogą się wiązać: osobowość typu A, podatność na stres oraz leczenie glikokortykosteroidami. Diagnostyka CSR obejmuje angiografię fluoresceinową i tomografię optyczną, w niektórych przypadkach wymagana jest angiografia indocyjaninowa. CSR jest chorobą samoograniczającą się, jednak w ok. 20% przypadków może przejść w formę przewlekłą. Laseroterapia wraz z iniekcjami anty-VEGF są skutecznymi metodami leczenia CSR. Terapie lekami doustnymi wydają się obiecujące, lecz wymagają dalszych badań.
Discipline
Publisher
Journal
Year
Volume
4
Issue
1
Pages
15-23
Physical description
References
  • 1. Pollock BD, Chen W, Harville EW, Bazzano LA. Associations between Hunter Type A/B Personality and Cardiovascular Risk Factors from Adolescence through Young Adulthood. Int J Behav Med 2017 Jan 26 [Epub ahead of print]. DOI: 10.1007/s12529-017-9636-5.
  • 2. Islam QU, Hanif MK, Tareen S. Frequency of Systemic Risk Factors in Central Serous Chorioretinopathy. J Coll Physicians Surg Pak 2016; 26(8): 692-695.
  • 3. Nudleman E, Witmer MT, Kiss S, et al. Central serous chorioretinopathy in patients receiving exogenous testosterone therapy. Retina 2014; 34(10): 2128-2132.
  • 4. Carvalho-Recchia CA, Yannuzzi LA, Negrao S, et al. Corticosteroids and central serous chorioretinopathy. Ophthalmology 2002; 109(10): 1834-1837.
  • 5. Casella AM, Berbel RF, Bressanim GL, et al. Helicobacter pylori as a potential target for the treatment of central serous chorioretinopathy. Clinics (Sao Paulo) 2012; 67(9): 1047-1052.
  • 6. Liew G, Quin G, Gillies M, Fraser-Bell S. Central serous chorioretinopathy: a review of epidemiology and pathophysiology. Clin Experiment Ophthalmol 2013; 41(2): 201-214.
  • 7. Zavoloka O, Bezditko P, Lahorzhevska I, et al. Clinical efficiency of Helicobacter pylori eradication in the treatment of patients with acute central serous chorioretinopathy. Graefes Arch Clin Exp Ophthalmol. 2016; 254(9): 1737-1742.
  • 8. Gomolin JE. Choroidal neovascularization and central serous chorioretinopathy. Can J Ophthalmol. 1989; 24(1): 20-23.
  • 9. Hua R, Yao K, Xia F, et al. The hyper-fluorescent transitional bands in ultra-late phase of indocyanine green angiography in chronic central serous chorioretinopathy. Lasers Surg Med 2016; 48(3): 260-263.
  • 10. Chen SJ, Lee AF, Lee FL, Liu JH. Indocyanine green angiography of central serous chorioretinopathy. Zhonghua Yi Xue Za Zhi (Taipei). 1999; 62(9): 605-613.
  • 11. Brandl C, Helbig H, Gamulescu MA. Choroidal thickness measurements during central serous chorioretinopathy treatment. Int Ophthalmol 2014; 34(1): 7-13.
  • 12. Tatham A, Macfarlane A. The use of propranolol to treat central serous chorioretinopathy: an evaluation by serial OCT. J Ocul Pharmacol Ther 2006; 22(2): 145-149.
  • 13. Nielsen JS, Jampol LM. Oral mifepristone for chronic central serous chorioretinopathy. Retina 2011; 31(9): 1928-1936.
  • 14. Khan MS, Sameen M, Lodhi AA, et al. Effect of half adult dose of oral Rifampicin (300 mg) in patients with idiopathic central serous chorioretinopathy. Pak J Med Sci. 2016; 32(5): 1158-1163.
  • 15. Shulman S, Goldenberg D, Schwartz R, et al. Oral Rifampin treatment for longstanding chronic central serous chorioretinopathy. Graefes Arch Clin Exp Ophthalmol 2016; 254(1): 15-22.
  • 16. Kurup SK, Oliver A, Emanuelli A, et al. Low-dose methotrexate for the treatment of chronic central serous chorioretinopathy: a retrospective analysis. Retina 2012; 32(10): 2096-2101.
  • 17. Cakir B, Fischer F, Ehlken C, et al. Clinical experience with eplerenone to treat chronic central serous chorioretinopathy. Graefes Arch Clin Exp Ophthalmol 2016; 254(11): 2151-2157.
  • 18. Pichi F, Carrai P, Ciardella A, et al.; Central Serous Chorioretinopathy Study Group. Comparison of two mineralcorticosteroids receptor antagonists for the treatment of central serous chorioretinopathy. Int Ophthalmol 2016; Oct 18 [Epub ahead of print]. DOI: 10.1007/ s10792-016-0377-2.
  • 19. Robertson DM, Ilstrup D. Direct, indirect, and sham laser photocoagulation in the management of central serous chorioretinopathy. Am J Ophthalmol 1983; 95(4): 457-466.
  • 20. Watzke RC, Burton TC, Woolson RF. Direct and indirect laser photocoagulation of central serous choroidopathy. Am J Ophthalmol 1979; 88(5): 914-918.
  • 21. Naseripour M, Falavarjani KG, Sedaghat A, et al. Half-dose Photodynamic Therapy for Chronic Central Serous Chorioretinopathy. J Ophthalmic Vis Res 2016; 11(1): 66-69.
  • 22. Breukink MB, Mohr JK, Ossewaarde-van Norel A, et al. Half-dose photodynamic therapy followed by diode micropulse laser therapy as treatment for chronic central serous chorioretinopathy: evaluation of a prospective treatment protocol. Acta Ophthalmol 2016; 94(2): 187-197.
  • 23. Özmert E, Demirel S, Yanık Ö, Batıoğlu F. Low-Fluence Photodynamic Therapy versus Subthreshold Micropulse Yellow Wavelength Laser in the Treatment of Chronic Central Serous Chorioretinopathy. J Ophthalmol 2016; 2016: 3513794.
  • 24. Tekin K, Sekeroglu MA, Cankaya AB, et al. Intravitreal Bevacizumab and Ranibizumab in the Treatment of Acute Central Serous Chorioretihopathy: A Single Center Retrospective Study. Semin Ophthalmol 2016; Nov 14: 1-6 [Epub ahead of print]. DOI: 10.1080/08820538.2016.1228985.
  • 25. Pitcher JD 3rd, Witkin AJ, DeCroos FC, Ho AC. A prospective pilot study of intravitreal aflibercept for the treatment of chronic central serous chorioretinopathy: the CONTAIN study. Br J Ophthalmol 2015; 99(6): 848-852.
  • 26. Bae SH, Heo J, Kim C, et al. Low-fluence photodynamic therapy versus ranibizumab for chronic central serous chorioretinopathy: one-year results of a randomized trial. Ophthalmology 2014; 121(2): 558-565.
Document Type
article
Publication order reference
YADDA identifier
bwmeta1.element.psjd-75bba944-f514-4c69-8e93-facc80312385
Identifiers
JavaScript is turned off in your web browser. Turn it on to take full advantage of this site, then refresh the page.